Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Hegenbart

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Blood Cancer Journal|July 30, 2016
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemiaS Kayser, A Benner, C Thiede, et al.
Leukemia|November 28, 2002
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced diseaseR Arnold, G Massenkeil, M Bornhäuser, et al.
Leukemia|April 1, 2005
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CMLF R Kerbauy, R Storb, U Hegenbart, et al.
Bone Marrow Transplantation|July 7, 2015
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapseM Hahn, S Böttcher, S Dietrich, et al.
Bone Marrow Transplantation|June 8, 2006
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myelomaN W C J van de Donk, N Kröger, U Hegenbart, et al.
QJM : Monthly Journal of the Association of Physicians|July 15, 2011
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effectsS W Dubrey, D E Reece, V Sanchorawala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparisonI Herth, S Dietrich, A Benner, et al.
Bone Marrow Transplantation|January 27, 2015
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trialS Iacobelli, L C de Wreede, S Schönland, et al.
Bone Marrow Transplantation|December 18, 2007
Allogeneic hematopoietic cell transplantation for metastatic breast cancerN T Ueno, J D Rizzo, T Demirer, et al.
Leukemia|December 28, 2016
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myelomaM I da Silva Filho, A Försti, N Weinhold, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Blood Cancer Journal|July 30, 2016
Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemiaS Kayser, A Benner, C Thiede, et al.
Leukemia|November 28, 2002
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced diseaseR Arnold, G Massenkeil, M Bornhäuser, et al.
Leukemia|April 1, 2005
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CMLF R Kerbauy, R Storb, U Hegenbart, et al.
Bone Marrow Transplantation|July 7, 2015
Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapseM Hahn, S Böttcher, S Dietrich, et al.
Bone Marrow Transplantation|June 8, 2006
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myelomaN W C J van de Donk, N Kröger, U Hegenbart, et al.
QJM : Monthly Journal of the Association of Physicians|July 15, 2011
Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effectsS W Dubrey, D E Reece, V Sanchorawala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparisonI Herth, S Dietrich, A Benner, et al.
Bone Marrow Transplantation|January 27, 2015
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trialS Iacobelli, L C de Wreede, S Schönland, et al.
Bone Marrow Transplantation|December 18, 2007
Allogeneic hematopoietic cell transplantation for metastatic breast cancerN T Ueno, J D Rizzo, T Demirer, et al.
Leukemia|December 28, 2016
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myelomaM I da Silva Filho, A Försti, N Weinhold, et al.
Pageof 6